PRIVA-PRAVASTATIN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

PRAVASTATIN SODIUM

Prieinama:

PHARMAPAR INC

ATC kodas:

C10AA03

INN (Tarptautinis Pavadinimas):

PRAVASTATIN

Dozė:

20MG

Vaisto forma:

TABLET

Sudėtis:

PRAVASTATIN SODIUM 20MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100/500

Recepto tipas:

Prescription

Gydymo sritis:

HMG-COA REDUCTASE INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0122563002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2022-07-29

Prekės savybės

_Priva-PRAVASTATIN _
_ _
_Page 1 of 37 _
PRODUCT MONOGRAPH
PR
PRIVA-PRAVASTATIN
Pravastatin Sodium Tablets, USP
10 mg, 20 mg and 40 mg
LIPID METABOLISM REGULATOR
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
September 1, 2015
Mont-Royal
Qc, H4T 1E2
Control # 186294
_Priva-PRAVASTATIN _
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
5
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
10
DRUG INTERACTIONS
..............................................................................................................
13
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
............................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
.....................................................................................
19
PHARMACEUTICAL INFORMATION
......................................................................................
19
C